Antiretroviral Therapy for Treatment and Prevention: Beyond Daily Oral Therapy - A New Frontier
Martin H. Markowitz MD
Anna and George Bobolas Professor of Clinical Research and Infectious Diseases
Aaron Diamond AIDS Research Center at Columbia University Irving Medical Center
Hammer Health Sciences, New York, NY
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2020. All rights reserved.
Martin Markowitz is a graduate of Stanford Medical School and completed his postgraduate training in Hematology/Oncology at Cornell Medical College and Infectious Diseases at New York University. Dr. Markowitz has worked at the Aaron Diamond AIDS Research Center (ADARC) since 1992 and currently holds the positions of Clinical Director and Staff Investigator. His seminal work in elucidating the dynamics of HIV-1 infection in vivo along with his mentor Dr. David Ho and colleagues at the Aaron Diamond AIDS Research Center formed the scientific foundation for triple combination therapy. In addition, his research interests have included the pathogenesis and treatment of acute HIV-1 infection, the fitness and transmission of drug-resistant HIV-1, and investigations of numerous novel antiretroviral agents as well as pathogenesis-based interventional trials. He was among the first to discuss HIV-1 cure, and perform trials of therapeutic vaccination and passive immunization as adjuncts to combination antiretroviral therapy.
At the completion of this educational session, learners will:
- Illustrate current recommendations for cART for HIV prevention and treatment and the need for alternatives to daily oral therapy.
- Review recent data for long acting cabotegravir (CAB LA) and long acting rilpivirine (RPV LA) for the treatment of HIV infection.Review recent data for long acting cabotegravir (CAB LA) and long acting rilpivirine (RPV LA) for the treatment of HIV infection.
- Present preclinical and clinical data of Cabotegravir LA and preclinical data of Islatravir for the prevention of HIV infection.
- Discuss broadly neutralizing antibodies (bNAbs) for the treatment and prevention of HIV infection.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare
Download Article PDF/Slides